HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase

Exp Hematol. 2013 Jul;41(7):646-55. doi: 10.1016/j.exphem.2013.03.002. Epub 2013 Mar 14.

Abstract

Stromal-derived factor (SDF)-1α, insulin-like growth factor (IGF)-1 and hepatocyte growth factor (HGF) are potent mediators of cell migration. We studied the effect of combinations of these cytokines on the migration of myeloma cells. When SDF-1α was combined with either HGF or IGF-1, we found a striking synergy in the cytokines' ability to guide cells across a transwell membrane. Between HGF and IGF-1 there was no cooperativity. However, the effects of HGF and IGF-1 were not redundant. HGF and SDF-1 caused concentration gradient-directed migration, as opposed to IGF-1, which apparently caused randomly directed cell movement. The SDF-1α-driven migration of JJN-3 cells, a myeloma cell line secreting large amounts of HGF, was reduced when JJN-3 cells were given an inhibitor of the HGF receptor, demonstrating a cooperative activity between autocrine HGF and exogenous SDF-1α. There was a clear positive correlation between the degree of cytokine-induced migration and phosphorylation of p21-activated kinase (PAK) both in primary myeloma cells and in cell lines including INA-6 and IH-1. Downregulation of PAK with small interfering RNA in INA-6 cells resulted in decreased cytokine-driven migration. This study shows synergy between SDF-1α and HGF/IGF-1 in inducing migration of myeloma cells, yet each cytokine has distinct properties in the way it regulates cell migration. These findings are likely to be of clinical relevance because multiple myeloma cells are located in an environment containing HGF and IGF-1 and are exposed to an SDF-1α gradient between the bone marrow and peripheral blood.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autocrine Communication
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Chemokine CXCL12 / pharmacology*
  • Chemokine CXCL12 / physiology
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Enzyme Activation
  • Hepatocyte Growth Factor / pharmacology*
  • Hepatocyte Growth Factor / physiology
  • Humans
  • Insulin-Like Growth Factor I / pharmacology*
  • Insulin-Like Growth Factor I / physiology
  • Multiple Myeloma / pathology*
  • Neoplasm Proteins / physiology
  • Proto-Oncogene Proteins c-met / drug effects
  • RNA, Small Interfering / pharmacology
  • Receptors, CXCR4 / physiology
  • Recombinant Fusion Proteins / physiology
  • Transfection
  • p21-Activated Kinases / antagonists & inhibitors
  • p21-Activated Kinases / genetics
  • p21-Activated Kinases / physiology*

Substances

  • CXCL12 protein, human
  • CXCR4 protein, human
  • Chemokine CXCL12
  • HGF protein, human
  • Neoplasm Proteins
  • RNA, Small Interfering
  • Receptors, CXCR4
  • Recombinant Fusion Proteins
  • Hepatocyte Growth Factor
  • Insulin-Like Growth Factor I
  • Proto-Oncogene Proteins c-met
  • PAK1 protein, human
  • PAK2 protein, human
  • p21-Activated Kinases